ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
285,710
285,710
363,468
312,690
252,002
Cost of revenue
984
984
3,100
5,322
4,212
Gross profit
284,726
284,726
360,368
307,368
247,790
Operating expenses
Research development
176,639
176,639
185,272
191,485
242,799
Selling general and administrative
176,303
176,303
230,855
332,493
317,418
Total operating expenses
352,942
352,942
416,127
523,978
560,217
Operating income or loss
-68,216
-68,216
-55,759
-216,610
-312,427
Interest expense
18,779
21,385
54,419
48,054
41,144
Total other income/expenses net
-85,257
-85,257
18,752
-10,216
8,890
Income before tax
-174,858
-174,858
-91,426
-274,880
-344,681
Income from continuing operations
-174,858
-174,858
-91,426
-274,880
-344,681
Net income
221,816
221,816
-91,426
-274,880
-344,681
Net income available to common shareholders
221,816
221,816
-91,426
-274,880
-344,681
Basic EPS
-
6.56
-2.87
-8.34
-10.89
Diluted EPS
-
6.56
-2.87
-8.34
-10.89
Basic average shares
-
33,837
31,894
32,970
31,654
Diluted average shares
-
33,837
31,894
32,970
31,654
EBITDA
-
-153,473
-37,007
-226,826
-303,537